Clinical overview of the seizure risk of dalfampridine.

Clinical overview of the seizure risk of dalfampridine.

Item
http://www.wikidata.org/entity/Q38019055
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis.Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States.Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial
P2860

Clinical overview of the seizure risk of dalfampridine.

Item
http://www.wikidata.org/entity/Q38019055
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical overview of the seizure risk of dalfampridine.
@en
type
label
Clinical overview of the seizure risk of dalfampridine.
@en
prefLabel
Clinical overview of the seizure risk of dalfampridine.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Clinical overview of the seizure risk of dalfampridine.
@en
P2093
P2860
P304
P31
P356
10.1517/14740338.2012.697896
P407
P433
P478
P577
P698
P921